Prosecution Insights
Last updated: August 16, 2026
Application No. 18/119,420

ZWITTERIONIC COMPOUND, PRODUCING METHOD THEREOF, POLYMER THEREOF, AND CONDUCTIVE STRUCTURE

Non-Final OA §112
Filed
May 26, 2023
Priority
Mar 10, 2022 — provisional 63/269,111
Examiner
NEAGU, IRINA
Art Unit
1764
Tech Center
1700 — Chemical & Materials Engineering
Assignee
National Yang Ming Chiao Tung University
OA Round
1 (Non-Final)
47%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allowance Rate
331 granted / 708 resolved
-18.2% vs TC avg
Strong +57% interview lift
Without
With
+57.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
54 currently pending
Career history
764
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
39.3%
-0.7% vs TC avg
§102
11.4%
-28.6% vs TC avg
§112
24.5%
-15.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 708 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Applicant’s preliminary amendment of 19 March 2026, in which claims 4-7 have been cancelled, is acknowledged. Claims 1-3, 8-15 are pending in the instant application. Claims 1-3, 8-15 are being examined on their merits herein. Priority This application claims the benefit of U.S. Provisional Patent Application 63/269,111, filed on 10 March 2022. Information Disclosure Statement The information disclosure statements (IDS) submitted on 26 May 2023 and 11 December 2024 are acknowledged and considered. Election/Restrictions Applicant’s election without traverse of Group I, claims 1-3, 8-15, drawn to a zwitterionic compound of formula (1), formula (2), formula (3), or formula (4), and to a method of producing a zwitterionic compound, in the reply filed on 19 March 2026, is acknowledged. Applicant has cancelled withdrawn claims 4-7. Objection to the Specification The Specification is objected to because the Scheme [0039] is confusing with respect to what is being formed in the first step (arrow without showing the reaction product). Claim objection Claim 1 is objected to because the recitation “A zwitterionic compound, having a structure of following formula (1), […]” could read --A zwitterionic compound of formula (1), […]--. Claim 2 is objected to because, for better clarity, it could read --The zwitterionic compound of claim 1, wherein the zwitterionic compound is of formula (1), wherein R1 is […]--. Claim 3 is objected to because it could read --The zwitterionic compound of claim 1, wherein the zwitterionic compound is of formula (1), wherein R1 is […]--. Claim Rejections- 35 USC 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 8 is drawn to a method of producing a zwitterionic compound, comprising: reacting an oxidizing agent, a lactone, or a sultone with a reactant to obtain the zwitterionic compound having the structure of formula (1) or formula (2) as claimed in claim 1, wherein the reactant has a structure of following formula (9) or formula (10): PNG media_image1.png 194 540 media_image1.png Greyscale The claim is confusing because it recites three different reactions between a reactant of formula (9) or of formula (10), and (1) an oxidizing agent; or (2) a lactone; or (3) a sultone, without providing the corresponding structures of the reaction products. To clarify the claim language, Applicant is invited to explain that, when a reactant of formula (9) or of formula (10) reacts with an oxidizing agent (list in claim 9), the reaction product is of formula (1) or (2) of claim 1, wherein R1 is -O-. Claim 8 could read –A method of producing the zwitterionic compound of claim 1, comprising reacting an oxidizing agent with a reactant of formula (9) or formula (10) PNG media_image2.png 188 522 media_image2.png Greyscale to obtain a zwitterionic compound of formula (1) or of formula (2), wherein R1 is -O-. – Claims 9, 10 (and 13) stay dependent on claim 8. A separate new claim could be added, drawn to a method of producing the zwitterionic compound of claim 1, comprising reacting a lactone with a reactant of formula (9) or formula (10) PNG media_image2.png 188 522 media_image2.png Greyscale to obtain a zwitterionic compound of formula (1) or of formula (2), wherein R1 is PNG media_image3.png 24 88 media_image3.png Greyscale . Claim 11 could be re-written to depend on this new claim, and define the size of the lactone. Claim 12 could be dependent on this new claim. A separate new claim could be added, drawn to a method of producing the zwitterionic compound of claim 1, comprising reacting a sultone with a reactant of formula (9) or formula (10) PNG media_image2.png 188 522 media_image2.png Greyscale to obtain a zwitterionic compound of formula (1) or of formula (2), wherein R1 is PNG media_image4.png 26 86 media_image4.png Greyscale . Dependent claims could be added, indicating the size of the sultone (as in claim 11), and the reaction temperature (as in claim 12). Claim 14 is indefinite because it is unclear what is the chemical identity of “a first compound”, it is unclear what is the chemical identity of “a second compound”, and what zwitterionic compound is being produced. Claim 14 could read –A method of producing the zwitterionic compound of claim 1, wherein the zwitterionic compound is of formula (3) or of formula (4), the method comprising reacting 3,4-dibromothiophene with PNG media_image5.png 62 144 media_image5.png Greyscale to form a first compound which is PNG media_image6.png 148 126 media_image6.png Greyscale ; reacting the first compound with PNG media_image7.png 80 114 media_image7.png Greyscale to form a second compound which is PNG media_image8.png 210 162 media_image8.png Greyscale ; and reacting the second compound with an amine selected from PNG media_image9.png 94 126 media_image9.png Greyscale and PNG media_image10.png 88 104 media_image10.png Greyscale to obtain the zwitterionic compound of formula (3) or of formula (4).-- Support for this amendment is found in the Specification, page 12. Claims 1-3, 8-15 are found free of the prior art. Cao et al. (Chem Sci 2016, 7, 1976-1981, cited in PTO-892) and Wu et al. (Langmuir 018, 34, 943-951, cited in IDS) describe the closest prior art, namely zwitterionic compounds PNG media_image11.png 132 148 media_image11.png Greyscale PNG media_image12.png 110 122 media_image12.png Greyscale Cao et al. Wu et al. as monomer precursors to polymers (PSBEDOT, Cao et al.) with antifouling and antimicrobial properties. The zwitterionic thiophene compounds disclosed by Cao and Wu are not anticipatory, nor do they render obvious a zwitterionic compound in the instant application, because a bicyclic 3,4-ethylenedioxythiophene (EDOT) core (Cao, Wu) is structurally distinct from a thiophene ring in the instant application. PNG media_image13.png 168 130 media_image13.png Greyscale PNG media_image14.png 192 162 media_image14.png Greyscale Instant application Conclusion Claims 1-3 are objected to. Claims 8-15 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to IRINA NEAGU whose telephone number is (571)270-5908. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY S. LUNDGREN can be reached on (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /IRINA NEAGU/Primary Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

May 26, 2023
Application Filed
Jul 06, 2026
Examiner Interview (Telephonic)
Jul 15, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12685721
AEROSOL COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
3y 11m to grant Granted Jul 21, 2026
Patent 12673921
SUBSTITUTED FLUORINE-CONTAINING IMIDAZOLE SALT COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
4y 8m to grant Granted Jul 07, 2026
Patent 12661407
COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF
2y 9m to grant Granted Jun 23, 2026
Patent 12648917
USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS
2y 5m to grant Granted Jun 09, 2026
Patent 12605347
SOLID DISPERSION OF URSOLIC ACID AND POTASSIUM SALT
3y 11m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
47%
Grant Probability
99%
With Interview (+57.4%)
2y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 708 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month